Scarica l'app Stockscreener
0.9104
42.63%
0.2721
Precedente Chiudi:
$0.6383
Aprire:
$0.797
Volume 24 ore:
30.65M
Relative Volume:
19.83
Capitalizzazione di mercato:
$6.39M
Reddito:
$5.75M
Utile/perdita netta:
$-38.96M
Rapporto P/E:
-0.073
EPS:
-12.47
Flusso di cassa netto:
$-32.63M
1 W Prestazione:
+43.82%
1M Prestazione:
+14.39%
6M Prestazione:
-77.47%
1 anno Prestazione:
-85.97%
Intervallo 1D:
$0.7013
$1.14
Intervallo di 1 settimana:
$0.6076
$1.14
Portata 52W:
$0.6076
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Nome
Kala Bio Inc
Settore
Industria
Telefono
781-996-5252
Indirizzo
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Confronta KALA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.9104 | 5.24M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Iniziato | Mizuho | Outperform |
| 2025-07-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-07-23 | Iniziato | Northland Capital | Outperform |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-27 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Kala Bio Inc Borsa (KALA) Ultime notizie
[Form 3] KALA BIO, Inc. Initial Statement of Beneficial Ownership - Stock Titan
[Form 4] KALA BIO, Inc. Insider Trading Activity - Stock Titan
Critical Review: REGENXBIO (NASDAQ:RGNX) versus KALA BIO (NASDAQ:KALA) - Defense World
What Sparked KALA BIO's Nearly 38% Surge Overnight? - Benzinga
Kala Bio IncOn Nov 21, board terminated without cause the employment of Mary Reumuth, company's chief financial officer - MarketScreener
KALA BIO, Inc. Announces Executive and Board Changes - TradingView
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits
KALA BIO, Inc. announced that it expects to receive $6 million in funding - MarketScreener
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What drives KALA BIO Inc stock priceMarket Rumors and News & Minimal Investment Portfolio Growth - earlytimes.in
Real time scanner hits for KALA BIO Inc. explainedEarnings Growth Summary & Weekly High Conviction Ideas - newser.com
KALA BIO: Q3 Earnings Snapshot - Connecticut Post
Is KALA BIO Inc. stock vulnerable to regulatory risksWeekly Trend Summary & Consistent Growth Equity Picks - newser.com
Chart based exit strategy for KALA BIO Inc.Trade Risk Assessment & Proven Capital Preservation Methods - newser.com
Will KALA BIO Inc. stock outperform international peersWeekly Investment Report & Weekly High Conviction Ideas - newser.com
Risk vs reward if holding onto KALA BIO Inc.Portfolio Update Summary & Free Risk Controlled Daily Trade Plans - newser.com
Is KALA BIO Inc. stock trading at a premium valuation2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - newser.com
KALA BIO, Inc. SEC 10-Q Report - TradingView
[10-Q] KALA BIO, Inc. Quarterly Earnings Report | KALA SEC FilingForm 10-Q - Stock Titan
Applying Elliott Wave Theory to KALA BIO Inc.Trade Exit Summary & Weekly High Return Forecasts - newser.com
Best data tools to analyze KALA BIO Inc. stockPortfolio Performance Report & Accurate Buy Signal Alerts - newser.com
Is KALA BIO Inc. stock supported by innovation pipelineWeekly Trend Report & Fast Gain Stock Tips - newser.com
Is KALA BIO Inc. stock a contrarian buyGap Down & Free High Accuracy Swing Entry Alerts - newser.com
Real time alert setup for KALA BIO Inc. performanceJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
What to do if you’re stuck in KALA BIO Inc.Trade Signal Summary & Free Community Supported Trade Ideas - newser.com
Will KALA BIO Inc. stock outperform value stocksJuly 2025 Recap & AI Enhanced Trading Alerts - newser.com
Kala Pharmaceuticals Delays Quarterly Report Filing - MSN
Detecting support and resistance levels for KALA BIO Inc.2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
[NT 10-Q] KALA BIO, Inc. SEC Filing - Stock Titan
Return on assets % of KALA BIO, Inc. – HAM:27F0 - TradingView
Long term debt to total assets ratio of KALA BIO, Inc. – HAM:27F0 - TradingView
Is KALA BIO Inc. stock a good choice for value investorsOptions Play & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Kala Bio Inc Azioni (KALA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kala Bio Inc Azioni (KALA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
0.76%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):